Income-Related Inequity in Initiation of Evidence-Based Therapies Among Patients with Acute Myocardial Infarction by Hanley, Gillian E. et al.
Income-Related Inequity in Initiation of Evidence-Based Therapies
Among Patients with Acute Myocardial Infarction
Gillian E. Hanley, PhD
1, Steve Morgan, PhD
1, and Robert J. Reid, MD, PhD
2
1Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia, Vancouver, BC,
Canada;
2Group Health Research Institute, Seattle, WA, USA.
BACKGROUND: Previous research has shown a socio-
economic status (SES) gradient in the receipt of cardiac
services following acute myocardial infarction (AMI), but
much less is known about SES and the use of
secondary preventive medicines following AMI.
OBJECTIVES: To examine the role of income in initia-
tion of treatment with ACE-inhibitors, beta-blockers
and statins in the 120 days following discharge from
hospital for first AMI.
DESIGN: A cross-sectional study with a population-
based cohort.
PARTICIPANTS: First-time AMI patients between age
40 and 100 discharged alive from the hospital and
surviving at least 120 days following discharge between
January 1, 1999 and September 3, 2006.
MAIN MEASURES: Binary variables indicating whether
the patient had filled at least one prescription for each
of the medicines of interest.
KEY RESULTS: Our results reveal a significant and
positive income gradient with initiation of the guide-
line-recommended medicines among male AMI
patients. Men in the third income quintile and above
were significantly more likely to initiate treatment
with any of the medicines than those in the first
quintile, with those in the fifth income quintile having
37%, 50% and 71% higher odds of initiating ACE-
inhibitors, beta-blockers and statins, respectively,
than men in the lowest income quintile [OR = 1.37
95% CI (1.24, 1.51); OR = 1.50 95% CI (1.35, 1.68);
and OR = 1.71 95% CI (1.53, 190)]. The gradient was
not present among women, although women in the
fifth income quintile were more likely to initiate beta-
blockers and statins than women in the lowest
income quintile [OR = 1.25 95% CI (1.06, 1.47) and
OR = 1.32 95% CI (1.12, 1.54)].
CONCLUSIONS: T h e r ew e r ei n e q u i t i e si nt r e a t m e n t
following AMI in the form of a clear and often signifi-
cant gradient between income and initiation of evi-
dence-based pharmacologic therapies among male
patients. This gradient persisted despite significant
changes in coverage levels for the costs of these
medicines.
KEY WORDS: access to care; cardiovascular disease; pharmaceutical
care; socioeconomic factors.
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INTRODUCTION
Despite Canada’s universal health insurance, research has
shown that socioeconomic status (SES) affects receipt of cardiac
procedures following an acute myocardial infarction (AMI):
previous studies have reported that AMI patients with higher
SES are more likely to receive cardiac catheterization
1,2 and
coronary angiography
3 than are more disadvantaged patients.
Some research has suggested that prescribing for secondary
prevention may be influenced by non-clinical factors such as
patient age and education
4. However, the potential relationship
between SES and receipt of recommended prescription medi-
cines following AMI remains unclear.
Pharmacologic therapy is safe and effective in the secondary
prevention of coronary artery disease. Generally accepted
clinical practice guidelines recommend that all patients without
contraindications or intolerance be treated with acetylsalicylic
acid (ASA), beta-blockers, angiotensin-converting enzyme (ACE)
inhibitors and cholesterol-lowering statins
5–7 to prevent sec-
ondary events. Guidelines recommend the combined use of all
four medicines as each of these agents has been shown to
reduce the risk of death and reinfarction
8–10, and combination
use provides the largest reduction in risk
11. Despite these
guidelines, we know that not all eligible AMI patients receive
these pharmacotherapies
12,13.
Given that all first-time AMI patients have the same level of
need for these therapies, if the health care system was achieving
its stated goals of promoting the use of effective medicines
according to need rather than ability-to-pay, we would expect no
significant differences in the initiation of recommended treat-
ment following AMI across income groups (as a measure of SES)
14,15. To test this (null) hypothesis, we performed a population-
based province-wide study of the initiation of treatment with
ACE-inhibitors, beta-blockers and statins in the 120 days
following discharge from the hospital for first AMI in British
Columbia (BC).
We also sought to determine whether the relationship
between income and initiation of these medicines persisted
after the drug benefits structure changed in BC. While
pharmaceuticals used in outpatient settings are not included
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Springerlink.comin the Canadian universal health insurance plan, prior to
May 2003 BC provided relatively comprehensive public drug
coverage for seniors (age ≥65), where seniors were responsi-
ble for small co-payson medicines up to an annual maximum
of $200 for low-income seniors and $275 for other seniors,
and a catastrophic coverage program for non-seniors (offering
70% coverage after $1,000 and 100% coverage after $4,333).
In May 2003, BC moved to a pharmacare program with
income-based coinsurance and deductibles regardless of
age, which increased the cost of medicines for many seniors
in the province
16,17. This policy change may have altered associa-
tions between income and access to medicines.
METHODS
We performed a cross-sectional study with a population-based
cohort. Our data sets include all residents of BC except those
whose health care is under federal jurisdiction: registered first
nations, veterans, RCMP and inmates of federal penitentiaries
(approximately 4% of the total population)
18.W ew e r ep r o v i d e d
data from Population Data BC and the BC PharmaNet with the
permission of the BC Ministry of Health Services and the BC
College of Pharmacists. Ethics approval was obtained from the
Behavioural Research Ethics Board at the University of British
Columbia.
STUDY POPULATION
Figure 1 outlines the exclusion criteria for our study popula-
tion. Using automated hospital discharge records, we identi-
fied all patients who were admitted between January 1, 1999
and September 3, 2006 to any acute care hospital in BC with a
primary diagnosis of AMI (ICD version 10 I21.x and ICD
version 9 410.x). We restricted our analysis to patients aged
40 to 100 years who were discharged alive between January 1,
1999 and September 3, 2006, and who had no previous
diagnosis of AMI during the 5 years prior. We identified
previous AMI by searching the hospital data for the 5 years
prior to the identified AMI to determine whether the patient
had been previously admitted to any acute care hospital in BC
with a primary diagnosis of AMI (same codes as above). The
first AMI event was considered the index AMI. We used the
ICD-10 diagnoses in the hospital discharge data for the index
AMI admission to eliminate patients with comorbidities that
could be considered contraindications to treatment with one or
more of the three medicines of interest. These included
cirrhosis, cholestatisis, chronic obstructive pulmonary disor-
der, asthma, bradycardia, end-stage renal disease and aortic
stenosis
19.
In order to ensure we had accurate health care and
prescription data for our study population, we also eliminated
individuals who were not registered for the provincial health
care program for at least 275 days in each of the 4 years prior
and the 1 year after their index AMI. Finally, we also eliminated
individuals who did not survive for 120 days and those who
were in long-term care settings in the year following their index
AMI.
DATA AND VARIABLE CONSTRUCTION
Prescription Drug Information. Prescription drug data were
obtained from the BC PharmaNet, which contains records of
all prescriptions filled at community pharmacies and long-
term care facilities in BC. Regardless of payer, pharmacists
enter medication names, dose and dispensed quantity for all
dispensed prescriptions into this database via a province-
wide network that ensures minimal reporting error and
misclassification
20. We used Anatomical Therapeutic
Classification (ATC) codes to identify medicines of interest:
ACE-inhibitors (ATC: C09), Beta Blockers (ATC: C07) and
Statins (ATC: C10A and C10B)
21. We built a variable
indicating whether or not a patient initiated if they filled at
least one prescription for the medicines listed above within the
120 days after discharge from hospital for their index AMI. We
did not include acetylsalicylic acid because it is also available
over-the-counter in British Columbia and thus would not be
completely captured in the BC PharmaNet.
Health Status and Residence Information. Popdata BC
maintains linkable data on all physician services and
All first time AMIs 
between Jan 1, 1999 
and Sep 3, 2006 
n= 39,704
First time AMIs 
between age 40 and 
100 
n=38,985 
Eliminated those under 
40 or over 100 years of 
age 
n=719 
First time AMI patients 
residing in BC for at 
least 275 days during 
relevant period 
n=31,957 
Eliminated those not 
residing in BC for 275 
days for 4 years before 
and 1 year after AMI
First time AMI patients 
who survived at least 
120 days post AMI 
n=30,656  Eliminated those with 
contraindications 
n=1,726 
Eliminated those in long
term care 
n=658 
Eliminated those missing 
sex info 
n=56
Final sample of first 
time AMI patients in 
BC between Jan 1, 
1999 and Sep 3, 2006 
n=28,216 
Eliminated patients who 
did not survive 120 days 
post AMI 
n=1,301 
n=7,028
Figure 1. Sample description information.
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discharge data include up to 25 diagnoses, while 1
diagnosis for each medical service is included. These data
sets have been shown to have good specificity and
completeness
22. We constructed measures of general health
status using the diagnosis-based Adjusted Clinical Group
(ACG) Case-Mix System
23. Specifically, we used the
Aggregated Diagnostic Groups, which were built from the
complement of ICD-9/ICD-10 diagnostic codes assigned in
inpatient and ambulatory settings over the 12-month period
prior to their index AMI. The ADGs have been shown to be
predictive of both prescription drug use and expenditure in
the BC population
24. A larger number of ADGs indicates a
higher comorbidity burden and worse health status. Our
indicator of urban residence was built using the Local
Health Area in which the patient resided at the time of
their index AMI. Local Health Areas that are located in
urban centres were used to build an indicator variable of
urban residence.
Income Information. Our income measure consisted of binary
variables indicating quintile groups ordered from lowest to
highest household incomes. For approximately 80% of the
population, the underlying income data were derived from
household-level incomes verified with the Canada Revenue
Agency by the BC Ministry of Health Services. For the
remaining AMI patients, we used a validated area-level
measure of the mean income of the neighborhood in which
they live, with neighborhoods including approximately 400–
700 residents
25.
STATISTICAL ANALYSIS
We compared average initiation rates across income quin-
tiles using F-tests to assess whether the mean rate of
initiation differed across income groups for both women
and men separately. We also ran sex-stratified multivariate
logistic regressions with four dependent variables indicating
initiation of treatment in the 120 days post-discharge on
ACE-inhibitors, beta-blockers, statins and all three of those
medicines. We controlled for age using 5-year bands, general
health status using the ADGs and an indicator of urban
residence. We also calculated sex-stratified crude rates of
initiation on each of those dependent variables. To examine
whether the relationships between income and treatment
changed after income-based coverage was introduced, we re-
ran the models with the addition of a policy change indicator
variable and interaction terms for each income quintile and
the policy change. If the relationship between the income
quintiles and initiation of treatment was significantly differ-
ent after the policy change, the coefficients on those
interaction terms would be significant. We also performed
several sensitivity analyses to test the effects of using
neighborhood-level income as well as individual-level income
and found that our results were robust. We also performed
sensitivity analyses examining the relationship between
income and initiation only among the sample of working
age AMI patients to examine potential confounding between
age and income. Again, we found that our results were
robust.
RESULTS
A total of 28,216 AMI patients met our eligibility criteria.
Patients were more likely to be male across all income
quintiles; however, this difference was more pronounced in
higher income quintiles (Table 1). This likely reflects the fact
that female AMI patients are older and thus less likely to be
earning employment income than their male counterparts.
Patients in the highest income quintile were slightly younger
than patients in other income quintiles. Those in the highest
income quintile were also slightly more likely to live in urban
areas and were generally in better health (as measured by their
fewer number of ADGs) than those in lower income quintiles. It
should be noted that for all sex-stratified analyses, sex-
stratified income quintiles were used, so there were equal
numbers of women in each income quintile, and our results
were not affected by the sex differences across income quintiles
reported in Table 1.
Crude rates of initiation of ACE-inhibitors, beta-blockers,
statins and all three medicines as well as 95% confidence
intervals are listed in Table 2. Table 2 also notes the mean
income in each quintile for both men and women. Men had
higher mean incomes in each quintile than women. For male
AMI patients, those in income quintiles 4 and 5 had signifi-
cantly higher rates of initiation for all medicines following AMI
than those in quintiles 1, 2 and 3. While the same was true for
women with respect to initiating treatment with beta-blockers,
there were generally fewer significant differences in initiation
rates across the income gradient for women. However, F-
statistics reject the null hypothesis that the mean rate of
initiation is the same across income quintiles for both men and
women and for all of the medicines studied (Table 2).
Tables 3 and 4 present adjusted odds ratios modeling the
relationship between income quintile and likelihood of initia-
Table 1. Distribution of Variables in the AMI Study Population
Income quintiles
Variable
(%)
1
(n = 5,644)
2
( n=5 , 6 4 3 )
3
( n=5 , 6 4 3 )
4
( n=5 , 6 4 3 )
5
( n=5 , 6 4 3 )
Sex
Male 55.0 61.8 66.1 73.5 79.8
Female 45.0 38.2 34.0 26.5 20.2
Age, years
40 to 49 8.7 6.5 7.8 8.4 13.4
50 to 59 18.5 13.2 15.3 20.0 32.2
60 to 69 23.9 22.2 23.5 26.8 24.2
70 to 79 23.4 31.0 31.3 28.6 19.3
80 to 89 20.4 23.6 19.4 14.8 9.9
90 to 99 5.1 3.6 2.7 1.5 0.9
Residence
Urban 74.5 70.1 69.5 75.9 78.3
Rural 25.5 29.9 30.5 24.1 21.7
General health status
Mean ADGs 7.5 7.3 7.1 7.0 6.7
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and all three medicines in the 120 days post-discharge from
hospital after first AMI in men and women, respectively. After
age, general health status and urban residence were
accounted for, men in the third income quintile or higher were
significantly more likely to initiate ACE-inhibitors, beta-block-
ers and statins than men in the first income quintile. Men in
the fifth income quintile had 37%, 50% and 71% higher odds of
initiating ACE-inhibitors, beta-blockers and statins, respec-
tively, than those in the lowest income quintile [OR = 1.37 95%
CI (1.24, 1.51); OR = 1.50 95% CI (1.35, 1.68); and OR = 1.71
95% CI (1.53, 190)]. Adhering with treatment guidelines and
initiating all three medicines was significantly more likely for
men in the 4th and 5th income quintiles [OR = 1.12 95% CI
(1.02, 1.24) and OR = 1.30 95% CI (1.18, 1.43)].
Table 4 suggests that the adjusted relationship between
household income and initiation of treatment is not as clear
among women. Women in the fourth income quintile were more
likely to initiate ACE-inhibitors than those in the lowest income
quintile [OR = 1.15 95% CI (1.01, 1.32)]. Women in the highest
income quintile were also significantly more likely to use beta-
blockersand statins than those inthe lowest incomequintile [OR
= 1.25 95% CI (1.06, 1.47) and OR = 1.32 95% CI (1.12, 1.54)].
There were no significant differences in initiation of treatment
with all three medicines; however, the mean rate of initiation on
all three medicines among women is a relatively low 36.0%.
As an example of the results found when examining the use
of medicines before and after the policy change, Table 5 contains
results of sex-stratified models describing use of ACE-inhibitors
and includes the policy change indicator and interaction terms.
None of the interaction terms between the income quintiles and
the policy change are significant in either of the sex-stratified
models, suggesting that the relationship between income and
initiation of treatment was not significantly affected by the
policy change. These interactions between income and the
policy change were insignificant in models for all dependent
variables studied (results available in an online appendix).
Models run separately pre-policy and post-policy also demon-
strated that income gradients existed before and after the policy
change (results also available in an online appendix).
DISCUSSION
In this population-based province-wide study, we demonstrat-
ed a clear and significant gradient between income and
initiation of evidence-based pharmacologic therapies post-
AMI among male patients. Given that we removed patients
with a contraindication for any of the recommended therapies
we studied, and that all of these patients were in equal need for
these effective treatments, we did not expect to see a significant
effect of income on use of these medicines. The significant
gradient between income and initiation of treatment did not
appear among female patients, although women in the highest
income quintiles were more likely to use statins and beta-
blockers than those in the lowest quintile. This may be partly
explained by the fact that the differences in mean income
across income quintiles were greater for male AMI patients
than for female AMI patients.
We also found that the relationship between income and
initiation of medicines did not significantly change despite a
policy change that substantially altered the way subsidies
Table 2. Crude Rates of Initiation of ACE-Inhibitors, Beta-Blockers, Statins and All Three Medicines in the 120 Days Post-Discharge from
Hospital for AMI
Income quintile (Mean income in quintiles) ACE-inhibitors (95% CI) Beta-blockers (95% CI) Statins (95% CI) All three (95% CI)
Men n = 3,795 n = 3,794 n = 3,794 n = 3,794
Quintile 1 ($14,800) 61.8 (60.3, 63.4) 68.1 (66.7, 70.0) 64.4 (62.9, 65.9) 42.8 (41.2, 44.3)
Quintile 2 ($28,500) 61.3 (59.7, 62.8) 67.6 (66.1, 69.0) 62.0 (60.4, 63.5) 39.4 (37.9, 41.0)
Quintile 3 ($38,450) 64.2 (62.6, 65.7) 72.0 (70.6, 73.4) 68.2 (66.7, 69.6) 43.3 (41.7, 44.9)
Quintile 4 ($54,600) 68.9 (67.4, 70.3) 75.7 (74.3, 77.0) 74.9 (73.6, 76.3) 48.8 (47.2, 50.4)
Quintile 5 ($105,000) 71.0 (70.4, 73.0) 78.8 (77.5, 80.1) 78.8 (77.4, 80.2) 52.4 (50.8, 54.0)
F-statistic 109.5 (p-value <0.0000) 163.4 (p-value <0.0000) 309.1 (p-value <0.0000) 120.0 (p-value <0.0000)
Women n = 1,849 n = 1,849 n = 1,849 n = 1,849
Quintile 1 ($11,400) 59.3 (57.0, 61.5) 66.1 (63.9, 68.2) 57.1 (54.8, 59.3) 33.5 (31.3, 35.6)
Quintile 2 ($22,900) 61.3 (59.0, 63.5) 67.2 (65.1, 69.4) 57.2 (55.0, 59.5) 33.4 (31.3, 35.6)
Quintile 3 ($30,500) 59.1 (56.9, 61.4) 69.1 (67.0, (71.1) 57.8 (55.5, 60.0) 34.1 (32.0, 36.3)
Quintile 4 ($40,400) 63.7 (61.5, 65.9) 70.0 (67.9, 72.1) 62.0 (59.8, 64.2) 35.9 (33.7, 38.1)
Quintile 5 ($82,150) 64.3 (62.1, 66.5) 74.0 (72.0, 76.0) 69.9 (67.8, 72.0) 42.9 (40.6, 45.1)
F-statistic 6.5 (p-value = 0.0110) 27.1 (p-value < 0.0000) 72.3 (p-value < 0.0000) 28.5 (p-value < 0.0000)
Table 3. Men: Regression Results for Initiation of ACE-Inhibitors, Beta-Blockers and Statins in the 120 Days Post-AMI by Income Quintile
ACE-inhibitors Beta-blockers Statins All three
Quintile 1 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Quintile 2 0.99 (0.89, 1.09) 1.04 (0.93, 1.15) 0.96 (0.87, 1.07) 0.93 (0.84, 1.03)
Quintile 3 1.13 (1.02, 1.25) 1.21 (1.09, 1.35) 1.15 (1.03, 1.28) 1.03 (0.93, 1.14)
Quintile 4 1.21 (1.09, 1.33) 1.35 (1.21, 1.51) 1.45 (1.30, 1.62) 1.12 (1.02, 1.24)
Quintile 5 1.37 (1.24, 1.51) 1.50 (1.35, 1.68) 1.71 (1.53, 1.90) 1.30 (1.18, 1.43)
Note: Adjusted for age using 5-year age bands, urban residence and general health status using Johns Hopkins ADGs
1332 Hanley et al.: Inequity in Medicine Use Following AMI JGIMwere allocated in BC during our study period. Given that
many of these patients faced very small copayments prior to
the policy change (maximum annual private payment of $200
or $275 annually), our finding might suggest that cost-
sharing may not be the only income-related barrier to
receiving these evidence-based medicines. Because we did
not have access to education data, we were unable to
determine whether there was confounding between education
and income that might explain the gradient we have seen.
For example, it is possible that low-income AMI patients were
less likely than high-income AMI patients to be fully aware of
the importance of adhering to their secondary preventive
therapies. However, our results might also indicate that even
very small copayments represent a large enough barrier to
discourage initiation and use among those of lower incomes.
Previous research illustrating that even very small copay-
ments often represent access barriers among vulnerable
populations supports this hypothesis
26–33.
Our results are consistent with a study from Denmark
that found that despite a generous health insurance system,
AMI patients with low income received secondary preventive
treatment with pharmacotherapies less frequently than their
higher income counterparts
34. Research in Sweden has also
suggested that adherence to these therapies following AMI is
higher among higher income patients
35,a n dA m e r i c a n
research has previously reported increased sensitivity to
copayments among patients living in lower income neigh-
bourhoods
36. We also know that Medicare patients with
more generous coverage consume more clinically essential
medicines
37,38, that increased cost-sharing is associated
with lower rates of drug treatment
26 and that approximately
20% of cardiovascular patients cut back on their medicines
because of cost
39. The consequences of cost-related non-
adherence or lack of initiation of recommended medical
treatment are particularly serious in AMI populations.
Cardiovascular patients not taking their medicines because
of cost have been shown to be at increased risk for both
hospitalization and death
32,39,40.
Our study is not without limitations. Our inability to
control for education means there could be some unob-
served confounding by education that is not acknowledged;
however, even if our results can be explained by differences
in education across income quintiles, they would still
indicate an important socioeconomic status gradient in care.
Given our use of administrative data, it is unlikely that our
attempt to exclude patients with contraindications to the
therapies under consideration captured all such patients.
We were also unable to identify patients who may have
experienced intolerance to one or more of these medicines
when using them for primary prevention. However, we would
not expect missed contraindications or intolerance to exhibit
an income gradient, and thus these limitations are unlikely
to seriously affect our main findings. We were also unable to
examine the use of ASA because the administrative data set
only captures prescription medicines, and many patients
may have been using ASA purchased over the counter.
However, the use of administrative data allowed us to
examine the entire population of patients suffering their
first AMI in the province between 1999 and 2006. Therefore,
our data are comprehensive, and not restricted to certain
care facilities or to certain age groups or sub-populations.
Another limitation is that our data only captured filled
prescriptions; we could not capture written but unfilled
prescriptions. We were also unable to control for the specialty
of the physician. Previous research has found that rates of
post-discharge use of statins and ACE-inhibitors are higher
in patients attended by cardiologists than noncardiologists
12.
Further research should examine whether the income gradi-
ent in initiation of treatment with recommended medicines
differs for those attended by cardiologists.
Our results suggest that there was a clear and positive
income gradient in filled prescriptions for the recommended
medicines shown to be safe and effective for secondary
prevention among male AMI patients. Physicians and phar-
macists should be aware that their lower income male AMI
patients may be at higher risk of not filling their prescrip-
tions, and advise and prescribe accordingly. Physicians may
Table 5. Regression Results Examining Whether the Relationship
Between Income and Initiation of ACE-Inhibitors Changed After
the Policy Change
Variable Men Women
Quintile 1 1.00 (ref) 1.00 (ref)
Quintile 2 1.03 (0.89, 1.18) 0.98 (0.83, 1.17)
Quintile 3 1.18 (1.03, 1.36) 0.96 (0.81, 1.14)
Quintile 4 1.24 (1.08, 1.42) 1.10 (0.91, 1.33)
Quintile 5 1.29 (1.12, 1.48) 1.03 (0.84, 1.27)
Post-policy indicator
variable
1.16 (0.99, 1.34) 0.82 (0.70, 0.97)
Quintile 1 pre-policy 1.00 (ref) 1.00 (ref)
Quintile 2 interacted
with post-policy variable
0.95 (0.78, 1.17) 0.97 (0.76, 1.24)
Quintile 3 interacted
with post-policy variable
0.93 (0.76, 1.14) 0.97 (0.75, 1.24)
Quintile 4 interacted
with post-policy variable
0.97 (0.79, 1.18) 1.06 (0.81, 1.38)
Quintile 5 interacted
with post-policy variable
1.18 (0.97, 1.45) 0.97 (0.72, 1.30)
Note: Adjusted for age using 5-year age bands, urban residence and
general health status using Johns Hopkins ADGs
Table 4. Women: Regression Results for Initiation of ACE-Inhibitors, Beta-Blockers and Statins in the 120 Days Post-AMI by Income Quintile
ACE-inhibitors Beta-blockers Statins All three
Quintile 1 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Quintile 2 1.01 (0.87, 1.11) 1.00 (0.88, 1.14) 0.94 (0.83, 1.06) 0.94 (0.83, 1.07)
Quintile 3 0.98 (0.89, 1.13) 1.05 (0.92, 1.20) 0.98 (0.86, 1.11) 0.91 (0.80, 1.04)
Quintile 4 1.15 (1.01, 1.32) 1.13 (0.97, 1.30) 1.07 (0.93, 1.23) 1.08 (0.94, 1.24)
Quintile 5 1.04 (0.89, 1.20) 1.25 (1.06, 1.47) 1.32 (1.12, 1.54) 1.09 (0.94, 1.27)
Note: Adjusted for age using 5-year age bands, urban residence and general health status using Johns Hopkins ADGs
1333 Hanley et al.: Inequity in Medicine Use Following AMI JGIMwant to prescribe generic and less expensive medicines, while
pharmacists may want to pay special attention to counseling
patients about the benefits of these medicines. Insurers
should also consider the potential benefits of providing these
m e d i c i n e sf r e eo fc o s tt oA M Ip a t i e n t s .Ar e c e n te c o n o m i c
evaluation conducted to explore the potential effects of full
public coverage of medicines for secondary prevention
reported that full coverage was cost-effective in the Canadian
system compared to the status quo, and resulted in greater
adjusted survival of AMI patients
41. Given that our research
suggests the potential to alleviate important income-related
inequities, and to significantly improve the number of AMI
patients receiving these recommended treatments, it may be
time for governments or insurers to seriously consider full
coverage for secondary prevention for AMI patients.
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